Naloxone is an opioid antagonist used to counter the effects of opioid overdose, such as morphine and heroine. Naloxone is indicated for use in opioid overdose to counteract life-threatening depression of the central nervous system and respiratory system, allowing an overdose victim to breathe normally. Naloxone is non-scheduled prescription medication, which in most cases, is administrated by emergency response personnel or minimally trained personnel, and is thus ideal for treating overdose in people who are prescribed opioid pain medication. Naloxone can be administrated through parenteral route, by injecting in the muscle or vein.

Request for Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1804

Naloxone Market Drivers

Opioids such as morphine, heroin, tramadol, oxycodone, and methadone have tendency to cause substance dependence, which is further characterized by a strong desire to take opioids, impaired control over opioid use, persistent opioid use despite harmful consequences, increased tolerance, and a physical withdrawal reaction when opioids are discontinued. Moreover, people dependent on opioids are most likely to suffer from drug overdose. Increasing number of opioid dependent patients, resulting in opioid overdose is expected to significantly increase demand for opioid antagonist medication, thereby increasing growth of naloxone market. According to the World Health Organization (WHO), November 2014 data sheet, around 69,000 people are estimated to die from opioid overdose each year, with 15 million people estimated to be suffering from opioid dependence (addiction to opioids). Among the total number of opioid dependence people, majority of are dependent on illicitly cultivated heroin, while an increasing proportion of people use prescription opioids. According to the United States Department of Health and Human Services (HHS), January 2018 updated data findings, in 2016, 42,249 people died from overdosing on opioids. Additionally, 2.1 million people misused prescription opioids for the first time.

Increasing engagement of government and private organizations in spreading awareness regarding availability of naloxone medications in the pharmacies and government approved co-payment programs to back the naloxone coverage throughout countries, worldwide, is expected to significantly increase growth of the naloxone market in the near future. The New York State Department of Health AIDS Institute offers benefits to people living in New York, through the Naloxone Co-payment Assistance Program (N-CAP). According to the N-CAP, individual with prescription coverage under the health insurance plan, can avail benefits upto US$ 40 for each prescription dispensed for co-payments of naloxone. Furthermore, according to the New York State- Department of Health, April 2018, revised data findings, individuals who are themselves or their family members or friends at risk for an overdose may acquire naloxone thorough over 2000 pharmacies in the New York State, without bringing in a prescription. World Health Organization (WHO), recommends naloxone as take-home antidote medication for people who likely to witness an opioid overdose.

Naloxone Market Restraints

Increasing gap between opioid overdose medication and its implementation is high. According to the WHO: November 2014, only 42% of countries provide access to effective treatment options for opioid dependence while less than 10% of people worldwide in need of opioid treatment have access to treatment. Limited accessibility to naloxone, in turn, poses as a major factor restraining growth of the naloxone market.

Request for TOC :  https://www.coherentmarketinsights.com/ongoing-insight/toc/1804

Naloxone Market – Regional Analysis

Geographically, the global naloxone market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. The North America naloxone market holds a major share in the global naloxone market, owing to increasing prevalence of opioid overdose, combined with growing number of healthcare regulatory organizations involved in offering opioid overdose treatment management options in the region.

For instance, in March 2016, Health Canada removed the prescription status for naloxone when used outside a hospital setting. After which, the College of Pharmacists of British Columbia, included naloxone in a Schedule II drug, making it available behind the counter of pharmacies in British Columbia. Furthermore, according to guidelines published in the Canadian Medical Association Journal, in March 2018, Canadian Medical Association recommends buprenorphine-naloxone as the preferred first-line treatment in opioid addiction. According to Canadian Medical Association Journal: March 2018, in 2016, in Canada, the rate of opioid-related deaths was 7.9 per 100,000 (a total of 2861 deaths), with the number of rapidly increasing. According to the data published by United Nations International narcotics Control Board: 2017, people in the U.S. consume more opioids than those in any other country, making the U.S. a lucrative market for growth of naloxone.

Naloxone Market – Competitor

Some of the key players operating in the global naloxone market are ADAPT Pharma, Inc., INSYS Therapeutics, Inc., Pfizer Inc., Amphastar Pharmaceuticals Inc., Mylan N.V., Opiant Technologies Inc., Kaleo, Inc., Alkermes, BioCorRx Inc., and Novartis International AG (Sandoz).

Naloxone Market Taxonomy

By Type

Branded

Generic

By Administration

Intranasal Administration

Intramuscular Administration

Intravenous Administration

By Distribution Channels:

Hospitals Pharmacies

Retail Pharmacies

Online Pharmacies

By Region

North America

Latin America

Europe

Asia Pacific

Middle East

Africa

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]